Similarly, Tanaka et al. revealed that using erythropoietin-stimulating agents was significantly correlated with reduced levels of CRP, a key marker of inflammation and cardiovascular disease, in patients with chronic kidney disease [27]. This evidence concerns the gene CRP and cardiovascular disorder.